Previously, a nested case-control study of a randomized controlled trial reported that anti-EPOR antibodies improved the prediction of kidney disease progression independent of traditional risk factors in patients with T2D at high CV risk.7 The gene discussed is EPOR; the disease is type 2 diabetes mellitus.